P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by Cycle
E. Kim(Harvard University), Corey J. Langer(University of Pennsylvania), Christopher Dakhil(Cancer Center of Kansas), Jonathan W. Goldman(University of California, Los Angeles), Robert M. Jotte(Sarah Cannon), Teng Jin Ong, Eric Anderson(Oregon Health & Science University), Amy Sanford, Kartik Konduri(Texas Oncology), Katayoun I. Amiri, J. Weiß(University of North Carolina at Chapel Hill), T. Berry, David C. Smith(University of Michigan), Daniel Haggstrom(Carolinas Healthcare System)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k